HealthEquity, Inc. (HQY) Director Sells $35,735.00 in Stock

HealthEquity, Inc. (NASDAQ:HQY) Director Frank Medici sold 700 shares of the business’s stock in a transaction on Wednesday, November 15th. The stock was sold at an average price of $51.05, for a total transaction of $35,735.00. Following the completion of the sale, the director now owns 6,381 shares in the company, valued at approximately $325,750.05. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Frank Medici also recently made the following trade(s):

  • On Friday, November 3rd, Frank Medici sold 32,404 shares of HealthEquity stock. The stock was sold at an average price of $51.09, for a total transaction of $1,655,520.36.
  • On Monday, November 6th, Frank Medici sold 419,504 shares of HealthEquity stock. The stock was sold at an average price of $52.97, for a total transaction of $22,221,126.88.
  • On Tuesday, October 24th, Frank Medici sold 7,900 shares of HealthEquity stock. The stock was sold at an average price of $51.11, for a total transaction of $403,769.00.
  • On Monday, October 9th, Frank Medici sold 316,644 shares of HealthEquity stock. The stock was sold at an average price of $51.96, for a total transaction of $16,452,822.24.

Shares of HealthEquity, Inc. (NASDAQ:HQY) traded down $0.57 during midday trading on Friday, hitting $50.17. 238,743 shares of the stock traded hands, compared to its average volume of 532,719. HealthEquity, Inc. has a 52-week low of $37.62 and a 52-week high of $55.31. The stock has a market cap of $3,070.00, a PE ratio of 79.00, a price-to-earnings-growth ratio of 2.18 and a beta of 1.77.

HealthEquity (NASDAQ:HQY) last posted its quarterly earnings data on Tuesday, September 5th. The company reported $0.27 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.14 by $0.13. HealthEquity had a net margin of 20.27% and a return on equity of 13.93%. The company had revenue of $56.90 million for the quarter, compared to analyst estimates of $55.66 million. During the same period in the prior year, the company posted $0.16 EPS. The firm’s revenue for the quarter was up 28.7% on a year-over-year basis. equities research analysts predict that HealthEquity, Inc. will post 0.7 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “HealthEquity, Inc. (HQY) Director Sells $35,735.00 in Stock” was first posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this news story can be read at https://ledgergazette.com/2017/11/17/healthequity-inc-hqy-director-sells-35735-00-in-stock.html.

A number of institutional investors have recently bought and sold shares of HQY. Janus Henderson Group PLC raised its position in HealthEquity by 627.9% in the 2nd quarter. Janus Henderson Group PLC now owns 2,113,030 shares of the company’s stock worth $105,292,000 after purchasing an additional 1,822,732 shares during the period. Eagle Asset Management Inc. purchased a new stake in HealthEquity in the 3rd quarter worth about $36,875,000. FMR LLC raised its position in HealthEquity by 45.6% in the 2nd quarter. FMR LLC now owns 2,235,150 shares of the company’s stock worth $111,378,000 after purchasing an additional 699,728 shares during the period. TimesSquare Capital Management LLC purchased a new stake in HealthEquity in the 2nd quarter worth about $25,822,000. Finally, Wells Fargo & Company MN raised its position in HealthEquity by 49.5% in the 3rd quarter. Wells Fargo & Company MN now owns 1,108,410 shares of the company’s stock worth $56,063,000 after purchasing an additional 366,925 shares during the period. 91.75% of the stock is currently owned by institutional investors.

Several brokerages have commented on HQY. Zacks Investment Research cut shares of HealthEquity from a “buy” rating to a “hold” rating in a research note on Wednesday. BidaskClub upgraded shares of HealthEquity from a “sell” rating to a “hold” rating in a research report on Thursday, September 28th. TheStreet upgraded shares of HealthEquity from a “c” rating to a “b” rating in a research report on Monday, July 31st. Robert W. Baird restated a “hold” rating on shares of HealthEquity in a research report on Thursday, September 21st. Finally, Oppenheimer Holdings, Inc. restated a “buy” rating and set a $61.00 target price on shares of HealthEquity in a research report on Wednesday, September 6th. Three analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $57.50.

HealthEquity Company Profile

HealthEquity, Inc provides a range of solutions for managing healthcare accounts (Health Savings Accounts (HSAs), Health Reimbursement Arrangements (HRAs) and Flexible Spending Accounts (FSAs)) for health plans, insurance companies and third-party administrators. The Company is engaged in technology-enabled services platforms that allow consumers to make healthcare saving and spending decisions.

Insider Buying and Selling by Quarter for HealthEquity (NASDAQ:HQY)

Receive News & Ratings for HealthEquity Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HealthEquity Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply